An Audience With in 2015

Filter By:

Article Type
Year

  • Vas Narasimhan, global head of development at Novartis, discusses his plans to increase the efficiency and reduce the cost of trial execution.

    An Audience With

  • Karen Midthun, outgoing Director of the FDA's Center for Biologics Evaluation and Research, reflects on 22 years at the agency.

    An Audience With

  • Husseini Manji, the Global Therapeutic Area Head of Neuroscience at Janssen, discusses the promise of NMDA receptor antagonists, anti-inflammatories and endocannabinoid modulators in psychiatry.

    An Audience With

  • Francis Cuss, Chief Scientific Officer of Bristol-Myers Squibb, discusses immuno-oncology, fibrosis and genetically defined diseases.

    An Audience With

  • Gloria Maldonado, Executive Director of Pfizer's Center of Excellence in Precision Medicine in Chile, discusses pharma's R&D expansion into Latin America.

    An Audience With

  • Pierre Meulien, soon to be the new Executive Director of The Innovative Medicines Initiative, discusses his plans to move the European public-private partnership forward.

    An Audience With

  • Moncef Slaoui, Chairman of Vaccines at GlaxoSmithKline, discusses the GSK–Novartis asset swap, the future of vaccines at GSK, and the implications for the company's remaining oncology programmes.

    An Audience With

  • Stéphane Bancel, Chief Executive Officer of Moderna, discusses the opportunity and scientific overhangs of mRNA therapeutics.

    An Audience With

  • Dirk Gevers, Head of the Janssen Human Microbiome Institute, discusses Janssen's plan to be a first mover in the microbiome space.

    An Audience With

  • Eric Karran, Director of Research at Alzheimer's Research UK, discusses his plan to shore up the Alzheimer's disease pipeline.

    An Audience With

  • Mike Varney, the new Head of Genentech Research and Early Development (gRED), discusses the culture of science at Genentech under Roche.

    An Audience With

  • Randy Mills, head of the California Institute for Regenerative Medicine (CIRM), discusses his plan for the stem-cell therapeutic funding agency.

    An Audience With